KALA BIO, Inc. (KALA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '19: 1.4M Q2 '19: 2.1M Q3 '19: 1.5M Q4 '19: 1.2M Q1 '20: 1.1M Q2 '20: 833K Q3 '20: 2.2M Q4 '20: 2.2M Q1 '21: 3.3M Q2 '21: 3.1M Q3 '21: 3.1M Q4 '21: 1.9M Q1 '22: 1.4M Q2 '22: 2.1M Q3 '22: 420K Q4 '22: 0 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -26.1M Q4 '21: -46.8M Q1 '22: -30.9M Q2 '22: -26M Q3 '22: -14.6M Q4 '22: -10.3M Q1 '23: -11.7M Q2 '23: -9.6M Q3 '23: -8.8M Q4 '23: -9.6M Q1 '24: -11.9M Q2 '24: -9.6M Q3 '24: -10M Q4 '24: -9.5M Q1 '25: -10.7M Q2 '25: -11M Q3 '25: -7.2M Q4 '25: -10.2M Q1 '26: -1.8M Q2 '26: -1.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -28.1M Q4 '21: -47.6M Q1 '22: -32.9M Q2 '22: -28.1M Q3 '22: 29.1M Q4 '22: -12.8M Q1 '23: -14.5M Q2 '23: -10.4M Q3 '23: -8.7M Q4 '23: -8.6M Q1 '24: -11.8M Q2 '24: -9.6M Q3 '24: -8.9M Q4 '24: -8.2M Q1 '25: -8.9M Q2 '25: -11.2M Q3 '25: -7.6M Q4 '25: 686K Q1 '26: -1.6M Q2 '26: -1.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 90K 180K 270K Q1 '19: 241K Q1 '19

Operating Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -26.1M Q4 '21: -27.9M Q1 '22: -24.1M Q2 '22: -25.4M Q3 '22: -15.7M Q4 '22: -13.7M Q1 '23: -9.7M Q2 '23: -7.6M Q3 '23: -3M Q4 '23: -7.7M Q1 '24: -10.8M Q2 '24: -9.2M Q3 '24: -4.7M Q4 '24: -4.6M Q1 '25: -8.8M Q2 '25: -16.6M Q3 '25: -10.9M Q4 '25: -4.6M Q1 '26: -2.9M Q2 '26: -1.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -8.2M Q4 '16: -7.4M Q1 '17: -9.4M Q2 '17: -8.9M Q3 '17: -9.4M Q4 '17: -6.8M Q1 '18: -13.1M Q2 '18: -9.4M Q3 '18: -16.3M Q4 '18: -16.9M Q1 '19: -31.6M Q2 '19: -20.9M Q3 '19: -23.1M Q4 '19: -18.4M Q1 '20: -20.2M Q2 '20: -19.9M Q3 '20: -26.2M Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '21: 61.7M Q2 '21: 64.6M Q3 '21: 1.3M Q1 '22: 1.5M Q2 '22: 1.5M Q3 '22: 1.5M Q1 '23: 2.1M Q2 '23: 2.4M Q3 '23: 2.6M Q1 '24: 2.8M Q2 '24: 3M Q3 '24: 4.6M Q1 '25: 126.9K Q2 '25: 130.3K Q3 '25: 7M Q1 '26: 11.9M Q2 '26: 74.2K Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-180.00 -120.00 -60.00 0.00 60.00 120.00 180.00 Q3 '21: -23.02 Q4 '21: -56.99 Q1 '22: -78.68 Q2 '22: -97.03 Q3 '22: -56.37 Q4 '22: -29.48 Q1 '23: -14.29 Q2 '23: 0.27 Q3 '23: -22.39 Q4 '23: -17.75 Q1 '24: -14.96 Q2 '24: -13.76 Q3 '24: -12.28 Q4 '24: -10.76 Q1 '25: -77.05 Q2 '25: -159.53 Q3 '25: -158.67 Q4 '25: -3.31 Q1 '26: 67.04 Q2 '26: 131.36 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.